Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Hemolytic-uremic syndrome future or investigational therapies
Introduction
Overview
Overview
Several disease-modifying treatments have been proposed for STEC-associated HUS, but effective targeted therapy remains unproven. Because Shiga toxin 2 has been identified in serum and in or on circulating blood cells and microvesicles shortly before or during HUS, extraintestinal Shiga toxin remains a potential therapeutic target. Until effective therapies are validated, management should focus on rapid diagnosis, close monitoring, avoidance of harmful interventions, prevention of volume depletion, and correction of modifiable risk factors.[1]
Future or Investigational Therapies
Future or Investigational Therapies
- ASA and dipyridamole not effective alone,benefit when added to plasma exchange
- In poorly responsive or resistant disease, INCREASE PLASMA EXCHANGE
- Then consider:
- prednisone (1 mg/kg per day)
- methylprednisolone (125 mg IV bid)
- Vincristine
- IVIG
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Sogand Goudarzi, MD [2] Parth Vikram Singh, MBBS[3]